Atomwise takes on 2 more JVs, including a $1.5B project with China's Hansoh Pharma

People shaking hands across a desk that has computer and papers on it
Atomwise will also work with Atropos Therapeutics to develop a pipeline of senescence-focused cancer treatments. (Pixabay)

When it rains, it pours: Following two new joint ventures, artificial-intelligence-based drug designer Atomwise has announced two more projects in quick succession—including one with a Chinese biopharma company it says could net the company up to $1.5 billion for developing first-in-class molecules. 

The collaboration with Hansoh Pharma, Atomwise’s first partner in Asia, aims to design new drug candidates for up to 11 undisclosed protein targets in different disease areas.  

Atomwise’s scientific teams in AI technology, medicinal chemistry and protein structure will work closely with Hansoh’s R&D, manufacturing and commercial staff, according to the two companies. In return, Atomwise will receive undisclosed technology access fees as well as option exercise fees and royalty payments. 


Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

RELATED: Atomwise inks 2 joint ventures in AI-based cancer drug development 

Meanwhile, Atomwise will work with California-based startup Atropos Therapeutics to develop a pipeline of cancer treatments.  

Atropos focuses on modulating cellular senescence, the regulated biological process that halts cell division and contributes to a normal part of aging. The failure and induction of senescence has also been linked to the progression of certain cancers.  

“This partnership with Atropos is an opportunity to ultimately provide patients with a fundamentally different class of drugs,” Atomwise co-founder and CEO Abraham Heifets, Ph.D., said in a statement

Under the agreement, the new joint venture company will be able to access tech from both Atropos and Atomwise to build out a new platform that screens compounds against anticancer targets. 

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

J&J and Ethicon reached a deal with the attorneys general of 41 states and DC, agreeing to pay nearly $117 million.